Russian Pharmaceutical Market 2021 Progress
According to DSM Group Marketing Company, the factors influencing Russian pharmaceutical market in 2021 included the COVID-19 pandemic, the rise in real disposable personal income, and high sales performance for pharmaceuticals produced in Russia.
Main conclusions:
·Retail trade revenue has reached 35.1 trillion RUB in the first 11 months of 2021, a 7.5% increase over last year, when the revenue fell by 4.1%. The largest increase was recorded in the second quarter of 2021.
·Pharmaceutical market capacity has increased by an average of 16% in end-user prices; the public procurement segment grew by 33%, and the retail pharmacy segment grew by 3.5%.
·Total pharmaceutical market capacity amounted to 2.295 trillion RUB without taking into account the COVID-19 vaccines; and 2.375 trillion RUB with the COVID-19 vaccines.
·Despite the market growth in rubles, there was a 7.7% fall in packaging. The reason for this could be the increase in packaging prices, as their weighted average cost grew by 12% (256 RUB).
·A sales growth was only observed in pharmaceuticals priced at over 500 RUB: an 11% increase in monetary value and a 9% increase in packaging.
·The highest price increase was recorded for localized pharmaceuticals produced in Russia.
·Russian manufacturers have demonstrated the highest sales performances of their own pharmaceuticals. The sales leaders were: Velpharm (increase of over 223% in rubles, market share of 0.1%), Lekpharm (increase of almost 91% in rubles, market share of 0.09%), PROMOMED RUS LLC (increase of 78.4% in rubles, market share of 0.32%).
·COVID-19 therapeutics remained the main growth drivers surpassing all others, especially during coronavirus waves.
According to analysts, Russia's pharmaceutical market capacity is estimated to grow by 5% and reach 2.5 trillion RUB in 2022. The capacity distribution is projected to be the following:
·commercial segment – over 1.3 trillion RUB;
·public procurement – 823 billion RUB;
·parapharmaceuticals – 344 billion RUB.
According to DSM Group Marketing Company, the factors influencing Russian pharmaceutical market in 2021 included the COVID-19 pandemic, the rise in real disposable personal income, and high sales performance for pharmaceuticals produced in Russia.
Main conclusions:
·Retail trade revenue has reached 35.1 trillion RUB in the first 11 months of 2021, a 7.5% increase over last year, when the revenue fell by 4.1%. The largest increase was recorded in the second quarter of 2021.
·Pharmaceutical market capacity has increased by an average of 16% in end-user prices; the public procurement segment grew by 33%, and the retail pharmacy segment grew by 3.5%.
·Total pharmaceutical market capacity amounted to 2.295 trillion RUB without taking into account the COVID-19 vaccines; and 2.375 trillion RUB with the COVID-19 vaccines.
·Despite the market growth in rubles, there was a 7.7% fall in packaging. The reason for this could be the increase in packaging prices, as their weighted average cost grew by 12% (256 RUB).
·A sales growth was only observed in pharmaceuticals priced at over 500 RUB: an 11% increase in monetary value and a 9% increase in packaging.
·The highest price increase was recorded for localized pharmaceuticals produced in Russia.
·Russian manufacturers have demonstrated the highest sales performances of their own pharmaceuticals. The sales leaders were: Velpharm (increase of over 223% in rubles, market share of 0.1%), Lekpharm (increase of almost 91% in rubles, market share of 0.09%), PROMOMED RUS LLC (increase of 78.4% in rubles, market share of 0.32%).
·COVID-19 therapeutics remained the main growth drivers surpassing all others, especially during coronavirus waves.
According to analysts, Russia's pharmaceutical market capacity is estimated to grow by 5% and reach 2.5 trillion RUB in 2022. The capacity distribution is projected to be the following:
·commercial segment – over 1.3 trillion RUB;
·public procurement – 823 billion RUB;
·parapharmaceuticals – 344 billion RUB.